Akt kinases in breast cancer and the results of adjuvant therapy
Open Access
- 1 April 2003
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 5 (2), 1-8
- https://doi.org/10.1186/bcr569
Abstract
The serine/threonine kinase Akt, or protein kinase B, has recently been a focus of interest because of its activity to inhibit apoptosis. It mediates cell survival by acting as a transducer of signals from growth factor receptors that activate phosphatidylinositol 3-kinase. We analysed the expression of the isoforms Akt1 and Akt2 as well as phosphorylated Akt (pAkt) by immunohistochemistry in frozen tumour samples from 280 postmenopausal patients who participated in a randomised trial comparing cyclophosphamide–methotrexate–5-fluorouracil chemotherapy and postoperative radiotherapy. The patients were simultaneously randomised to tamoxifen or to no endocrine treatment. Marked staining was found in 24% of the tumours for Akt1, but in only 4% for Akt2. A low frequency of Akt2-positive cells (1–10%) was observed in another 26% of the tumours. pAkt was significantly associated with both Akt1 and Akt2 expression. Overexpression of erbB2 correlated significantly with pAkt (P = 0.0028). The benefit from tamoxifen was analysed in oestrogen receptor (ER)-positive patients. Patients with a negative status of Akt (no overexpression of Akt1, Akt2 or pAkt) showed significant benefit from tamoxifen. The relative rate of distant recurrence, with versus without tamoxifen, was 0.44 (95% confidence interval [CI], 0.25–0.79) for ER+/Akt1- patients, while it was 0.72 (95% CI, 0.34–1.53) for ER+/Akt1+ patients. The difference in rate ratio did not reach statistical significance. The rate of locoregional recurrence was significantly decreased with radiotherapy versus chemotherapy for Akt-negative patients (rate ratio, 0.23; 95% CI, 0.08–0.67; P = 0.0074), while no benefit was evident for the Akt-positive subgroup (rate ratio, 0.77; 95% CI, 0.31–1.9; P = 0.58). The interaction between Akt and the efficacy of radiotherapy was significant in multivariate analysis (P = 0.042). Activation of the Akt pathway is correlated with erbB2 overexpression in breast cancer. The results suggest that Akt may predict the local control benefit from radiotherapy.Keywords
This publication has 48 references indexed in Scilit:
- Oncogenic transformation induced by membrane-targeted Akt2 and Akt3Oncogene, 2001
- Matrix detachment induces caspase-dependent cytochrome c release from mitochondria: inhibition by PKB/Akt but not Raf signallingOncogene, 2000
- The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cellsOncogene, 1999
- The Regulation and Activities of the Multifunctional Serine/Threonine Kinase Akt/PKBExperimental Cell Research, 1999
- Identification of a Human Akt3 (Protein Kinase B γ) Which Contains the Regulatory Serine Phosphorylation SiteBiochemical and Biophysical Research Communications, 1999
- Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulinOncogene, 1998
- Amplification and overexpression of theAKT2 oncogene in a subset of human pancreatic ductal adenocarcinomasMolecular Carcinogenesis, 1998
- Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase AktScience, 1997
- Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trialsInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958